journal article·2025-05-19Open access

Nano/Micro-Enabled Modification and Innovation of Conventional Adjuvants for Next-Generation Vaccines

Xingchi Liu, Xu Yang, Lu Tao, Xuanchen Li, Guoqiang Chen, Qi Liu

Abstract

The global spread of infectious diseases has raised public awareness of vaccines, highlighting their essential role in protecting public health. Among the components of modern vaccines, adjuvants have received increasing attention for boosting immune responses and enhancing efficacy. Recent advancements in adjuvant research, particularly nanodelivery systems, have paved the way for developing more effective and safer adjuvants. This review outlines the properties, progress, and mechanisms of FDA-approved conventional adjuvants, focusing on their contributions to and challenges in vaccine success. Despite these advancements, conventional adjuvants still face suboptimal immunomodulatory effects, potential side effects, and limitations in targeting specific immune pathways. Nanodelivery systems have emerged as a transformative approach in adjuvant design, offering unique advantages such as enhancing vaccine stability, enabling controlled antigen release, and inducing specific immune responses. By addressing these limitations, nanocarriers improve the safety and efficacy of conventional adjuvants and drive the development of next-generation adjuvants for complex diseases. This review also explores strategies for incorporating nanodelivery systems into adjuvant development, emphasizing its role in optimizing vaccine formulations. By summarizing current challenges and recent advances, this review aims to provide valuable insights guiding future efforts in designing innovative adjuvants that meet the evolving needs of global immunization programs.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · SARS-CoV-2 and COVID-19 Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Engineering Medicine, Beihang University, Beijing 100191, China

State Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Beijing 100190, China

Funding

National Natural Science Foundation of China · Beijing Natural Science Foundation · Fundamental Research Funds for the Central Universities

References (100+)

Show source-provided references
1. Pore geometry of etched ion tracks in polyimide10.1016/0168-583X(95)01264-8 ↗
2. Gerhard, W., Mozdzanowska, K., and Zharikova, D. (2006). Prospects for Universal Influenza Virus Vaccine. Emerg. Infect. Dis., 12.10.3201/eid1204.051020 ↗
3. Analyses of the 2023 Nobel Prize in Physiology or Medicine: Nucleoside Base Modifications and Effective mRNA Vaccines10.1080/0194262X.2023.2292047 ↗
4. Ghattas, M., Dwivedi, G., Lavertu, M., and Alameh, M.-G. (2021). Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities. Vaccines, 9.10.3390/vaccines9121490 ↗
5. Xue, J.-B., Lai, D.-Y., Jiang, H.-W., Qi, H., Guo, S.-J., Zhu, Y.-S., Xu, H., Zhou, J., and Tao, S.-C. (2022). Landscape of the RBD-specific IgG, IgM, and IgA responses triggered by the inactivated virus vaccine against the Omicron variant. Cell Discov., 8.10.1038/s41421-022-00380-8 ↗
6. Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Induced by Natural Infection or Vaccination: A Systematic Review and Pooled Analysis10.1093/cid/ciab646 ↗
7. Measles-Mumps-Rubella-Varicella Combination Vaccine and the Risk of Febrile Seizures10.1542/peds.2010-0665 ↗
8. Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination10.1016/j.vaccine.2013.12.011 ↗
9. Long-Term Prognosis of Patients With Myocarditis Attributed to COVID-19 mRNA Vaccination, SARS-CoV-2 Infection, or Conventional Etiologies10.1001/jama.2024.16380 ↗
10. Intrathecal antibody production in two cases of yellow fever vaccine associated neurotropic disease in Argentina10.1002/jmv.22236 ↗
11. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices10.15585/mmwr.rr6701a1 ↗
12. Insufficient epitope-specific T cell clones are responsible for impaired cellular immunity to inactivated SARS-CoV-2 vaccine in older adults10.1038/s43587-023-00379-0 ↗
13. Prenatal development of human immunity10.1126/science.aaz9330 ↗
14. Influence of protein fold stability on immunogenicity and its implications for vaccine design10.1080/14760584.2017.1306441 ↗
15. Subunit Vaccines of the Future: The Need for safe, Customized and Optimized Particulate Delivery Systems10.4155/tde.11.68 ↗
16. Immune response to functionalized mesoporous silica nanoparticles for targeted drug delivery10.1039/C5NR06122A ↗
17. Enhancement of Immune Responses Elicited by Nanovaccines through a Cross-Presentation Pathway10.1007/s13770-023-00527-y ↗
18. Farasati Far, B., Naimi-Jamal, M.R., Safaei, M., Zarei, K., Moradi, M., and Yazdani Nezhad, H. (2022). A Review on Biomedical Application of Polysaccharide-Based Hydrogels with a Focus on Drug Delivery Systems. Polymers, 14.10.3390/polym14245432 ↗
19. Hou, Y., Chen, M., Bian, Y., Hu, Y., Chuan, J., Zhong, L., Zhu, Y., and Tong, R. (2024). Insights into vaccines for elderly individuals: From the impacts of immunosenescence to delivery strategies. NPJ Vaccines, 9.10.1038/s41541-024-00874-4 ↗
20. Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and disease10.1038/nri.2015.8 ↗
21. Control of adaptive immunity by pattern recognition receptors10.1016/j.immuni.2024.03.014 ↗
22. Martiñón, S., Cisneros, A., Villicaña, S., Hernández-Miramontes, R., Mixcoha, E., and Calderón-Vargas, P. (2019). Chemical and Immunological Characteristics of Aluminum-Based, Oil-Water Emulsion, and Bacterial-Origin Adjuvants. J. Immunol. Res., 2019.10.1155/2019/3974127 ↗
23. Optimising the oil phases of aluminium hydrogel-stabilised emulsions for stable, safe and efficient vaccine adjuvant10.1007/s11705-021-2123-1 ↗
24. Immunogenicity and efficacy of recombinant subunit vaccines against phocid herpesvirus type 110.1016/S0264-410X(03)00056-2 ↗
25. Ulmer, J. (2013). Vaccine Adjuvants: Mode of Action. Front. Immunol., 4.10.3389/fimmu.2013.00214 ↗
26. Pedersen, G.K., Wørzner, K., Andersen, P., and Christensen, D. (2020). Vaccine Adjuvants Differentially Affect Kinetics of Antibody and Germinal Center Responses. Front. Immunol., 11.10.3389/fimmu.2020.579761 ↗
27. Working together: Interactions between vaccine antigens and adjuvants10.1177/2051013613480144 ↗
28. Vaccine adjuvants: Current status, research and development, licensing, and future opportunities10.1039/D3TB02861E ↗
29. Universal and Translational Nanoparticulate CpG Adjuvant10.1021/acsami.2c15644 ↗
30. Morphologically Virus-Like Fullerenol Nanoparticles Act as the Dual-Functional Nanoadjuvant for HIV-1 Vaccine10.1002/adma.201300583 ↗
31. Moni, S.S., Abdelwahab, S.I., Jabeen, A., Elmobark, M.E., Aqaili, D., Gohal, G., Oraibi, B., Farasani, A.M., Jerah, A.A., and Alnajai, M.M.A. (2023). Advancements in Vaccine Adjuvants: The Journey from Alum to Nano Formulations. Vaccines, 11.10.3390/vaccines11111704 ↗
32. Barbateskovic, M., Klingenberg, S.L., Krauss, S.R., Kong, D., Wu, Z., Petersen, S.B., Kenfelt, M., and Gluud, C. (2023). Concentrations, Number of Doses, and Formulations of Aluminium Adjuvants in Vaccines: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Clinical Trials. Vaccines, 11.10.3390/vaccines11121763 ↗
33. Laera, D., HogenEsch, H., and O’Hagan, D.T. (2023). Aluminum Adjuvants—‘Back to the Future’. Pharmaceutics, 15.10.3390/pharmaceutics15071884 ↗
34. Recent advances in vaccine adjuvants: The development of MF59 emulsion and polymeric microparticles10.1016/S1357-4310(96)10058-7 ↗
35. Safety of AS03-adjuvanted influenza vaccines: A review of the evidence10.1016/j.vaccine.2019.04.048 ↗
36. Adjuvant system AS01: Helping to overcome the challenges of modern vaccines10.1080/14760584.2016.1213632 ↗
37. Hoxie, I., Vasilev, K., Clark, J.J., Bushfield, K., Francis, B., Loganathan, M., Campbell, J.D., Yu, D., Guan, L., and Gu, C. (2024). A recombinant N2 neuraminidase-based CpG 1018® adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamsters. Vaccine, 42.10.1016/j.vaccine.2024.126269 ↗
38. Li, Y., Wu, W., Liu, Q., Wu, Q., Ren, P., Xi, X., Liu, H., Zhao, J., Zhang, W., and Wang, Z. (2024). Specific surface-modified iron oxide nanoparticles trigger complement-dependent innate and adaptive antileukaemia immunity. Nat. Commun., 15.10.1038/s41467-024-54810-0 ↗
39. Croitoru, G.-A., Pîrvulescu, D.-C., Niculescu, A.-G., Epistatu, D., Rădulescu, M., Grumezescu, A.M., and Nicolae, C.-L. (2024). Nanomaterials in Immunology: Bridging Innovative Approaches in Immune Modulation, Diagnostics, and Therapy. J. Funct. Biomater., 15.10.3390/jfb15080225 ↗
40. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting10.1056/NEJMoa2101765 ↗
41. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants10.1038/s41586-021-03693-y ↗
42. Gu, Y., Chen, J., Wang, Z., Liu, C., Wang, T., Kim, C.-J., Durikova, H., Fernandes, S., Johnson, D.N., and De Rose, R. (2024). mRNA delivery enabled by metal–organic nanoparticles. Nat. Commun., 15.10.1038/s41467-024-53969-w ↗
43. Fusogenic Coiled-Coil Peptides Enhance Lipid Nanoparticle-Mediated mRNA Delivery upon Intramyocardial Administration10.1021/acsnano.3c05341 ↗
44. Use of COVID-19 Vaccines for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices—United States, 2024–202510.15585/mmwr.mm7337e2 ↗
45. Engineering Self-Assembling Protein Nanoparticles for Therapeutic Delivery10.1021/acs.bioconjchem.2c00030 ↗
46. Ikwuagwu, B., and Tullman-Ercek, D. (2022). Virus-like particles for drug delivery: A review of methods and applications. Curr. Opin. Biotechnol., 78.10.1016/j.copbio.2022.102785 ↗
47. Yang, J.-X., Tseng, J.-C., Yu, G.-Y., Luo, Y., Huang, C.-Y.F., Hong, Y.-R., and Chuang, T.-H. (2022). Recent Advances in the Development of Toll-like Receptor Agonist-Based Vaccine Adjuvants for Infectious Diseases. Pharmaceutics, 14.10.3390/pharmaceutics14020423 ↗
48. Facciolà, A., Visalli, G., Laganà, A., and Di Pietro, A. (2022). An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives. Vaccines, 10.10.3390/vaccines10050819 ↗
49. Zhao, T., Cai, Y., Jiang, Y., He, X., Wei, Y., Yu, Y., and Tian, X. (2023). Vaccine adjuvants: Mechanisms and platforms. Signal Transduct. Target. Ther., 8.10.1038/s41392-023-01557-7 ↗
50. mRNA vaccine designs for optimal adjuvanticity and delivery10.1080/15476286.2024.2333123 ↗
51. Recombinant H5 hemagglutinin adjuvanted with nanoemulsion protects ferrets against pathogenic avian influenza virus challenge10.1016/j.vaccine.2019.02.002 ↗
52. Zhang, T., He, P., Guo, D., Chen, K., Hu, Z., and Zou, Y. (2023). Research Progress of Aluminum Phosphate Adjuvants and Their Action Mechanisms. Pharmaceutics, 15.10.3390/pharmaceutics15061756 ↗
53. Re-inventing traditional aluminum-based adjuvants: Insight into a century of advancements10.1080/08830185.2024.2404095 ↗
54. From antigen uptake to immune modulation: The multifaceted potential of peptide nanofibers as vaccine nanocarriers10.1039/D4MA00075G ↗
55. Enhanced Immune Adjuvant Activity of Aluminum Oxyhydroxide Nanorods through Cationic Surface Functionalization10.1021/acsami.7b05817 ↗
56. Büyükbayraktar, H.K., Pelit Arayıcı, P., Ihlamur, M., Gökkaya, D., Karahan, M., Abamor, E.Ş., and Topuzoğulları, M. (2023). Effect of polycation coating on the long-term pulsatile release of antigenic ESAT-61–20 peptide from PLGA nanoparticles. Colloids Surf. B, 228.10.1016/j.colsurfb.2023.113421 ↗
57. Liang, Z., Bao, H., Yao, Z., Li, M., Chen, C., Zhang, L., Wang, H., Guo, Y., Ma, Y., and Yang, X. (2024). The orientation of CpG conjugation on aluminum oxyhydroxide nanoparticles determines the immunostimulatory effects of combination adjuvants. Biomaterials, 308.10.1016/j.biomaterials.2024.122569 ↗
58. Lipid nanoparticles for mRNA delivery10.1038/s41578-021-00358-0 ↗
59. Engineering nanomaterial physical characteristics for cancer immunotherapy10.1038/s44222-023-00047-3 ↗
60. Development of a minimal saponin vaccine adjuvant based on QS-2110.1038/nchem.1963 ↗
61. Functionalization of immunostimulating complexes (ISCOMs) with lipid vinyl sulfones and their application in immunological techniques and therapy10.2147/IJN.S35556 ↗
62. The antigenic value of toxoid precipitated by potassium alum
63. HogenEsch, H. (2013). Mechanism of Immunopotentiation and Safety of Aluminum Adjuvants. Front. Immunol., 3.10.3389/fimmu.2012.00406 ↗
64. Emerging concepts in the science of vaccine adjuvants10.1038/s41573-021-00163-y ↗
65. Hem, S.L., and Johnston, C.T. (2014). Production and Characterization of Aluminum-Containing Adjuvants. Vaccine Development and Manufacturing, John Wiley & Sons.10.1002/9781118870914.ch11 ↗
66. Shardlow, E., Mold, M., and Exley, C. (2018). Unraveling the enigma: Elucidating the relationship between the physicochemical properties of aluminium-based adjuvants and their immunological mechanisms of action. Allergy Asthma Clin. Immunol., 14.10.1186/s13223-018-0305-2 ↗
67. Effect of Anions on Model Aluminum-Adjuvant-Containing Vaccines10.1006/jcis.1995.1233 ↗
68. Lu, Y., and Liu, G. (2022). Nano alum: A new solution to the new challenge. Hum. Vaccines Immunother., 18.10.1080/21645515.2022.2060667 ↗
69. Liang, Z., Wang, X., Yu, G., Li, M., Shi, S., Bao, H., Chen, C., Fu, D., Ma, W., and Xue, C. (2022). Mechanistic understanding of the aspect ratio-dependent adjuvanticity of engineered aluminum oxyhydroxide nanorods in prophylactic vaccines. Nano Today, 43.10.1016/j.nantod.2022.101445 ↗
70. Chen, W., Zuo, H., Li, B., Duan, C., Rolfe, B., Zhang, B., Mahony, T.J., and Xu, Z.P. (2018). Clay Nanoparticles Elicit Long-Term Immune Responses by Forming Biodegradable Depots for Sustained Antigen Stimulation. Small, 14.10.1002/smll.201704465 ↗
71. Efficient and Durable Vaccine against Intimin β of Diarrheagenic E. coli Induced by Clay Nanoparticles10.1002/smll.201503359 ↗
72. Toward understanding the mechanism underlying the strong adjuvant activity of aluminum salt nanoparticles10.1016/j.vaccine.2016.04.081 ↗
73. Orr, M.T., Khandhar, A.P., Seydoux, E., Liang, H., Gage, E., Mikasa, T., Beebe, E.L., Rintala, N.D., Persson, K.H., and Ahniyaz, A. (2019). Reprogramming the adjuvant properties of aluminum oxyhydroxide with nanoparticle technology. NPJ Vaccines, 4.10.1038/s41541-018-0094-0 ↗
74. Uric acid and the vaccine adjuvant activity of aluminium (oxy)hydroxide nanoparticles10.1080/1061186X.2018.1428808 ↗
75. Stabilised aluminium phosphate nanoparticles used as vaccine adjuvant10.1016/j.colsurfb.2019.06.024 ↗
76. Mechanistic study of the adjuvant effect of chitosan-aluminum nanoparticles10.1016/j.ijpharm.2018.09.044 ↗
77. Alum-functionalized graphene oxide nanocomplexes for effective anticancer vaccination10.1016/j.actbio.2018.11.023 ↗
78. Jiang, H., Wang, Q., Li, L., Zeng, Q., Li, H., Gong, T., Zhang, Z., and Sun, X. (2018). Turning the Old Adjuvant from Gel to Nanoparticles to Amplify CD8+ T Cell Responses. Adv. Sci., 5.10.1002/advs.201700426 ↗
79. Li, D., Xu, M., Li, G., Zheng, Y., Zhang, Y., Xia, D., Wang, S., and Chen, Y. (2022). Mg/Al-LDH as a nano-adjuvant for pertussis vaccine: A evaluation compared with aluminum hydroxide adjuvant. Nanotechnology, 33.10.1088/1361-6528/ac56f3 ↗
80. Engineering an Effective Immune Adjuvant by Designed Control of Shape and Crystallinity of Aluminum Oxyhydroxide Nanoparticles10.1021/nn404211j ↗
81. Applications of nanomaterials as vaccine adjuvants10.4161/hv.29589 ↗
82. Nanoparticles and Vaccine Development10.2174/2211738507666191024162042 ↗
83. Nanomaterial-based vaccine adjuvants10.1039/C6TB01131D ↗
84. Nazarizadeh, A., Staudacher, A.H., Wittwer, N.L., Turnbull, T., Brown, M.P., and Kempson, I. (2022). Aluminium Nanoparticles as Efficient Adjuvants Compared to Their Microparticle Counterparts: Current Progress and Perspectives. Int. J. Mol. Sci., 23.10.3390/ijms23094707 ↗
85. Protective Efficacy of the Killed Toxoplasma gondii Vaccine in Nano-alum Adjuvant
86. Self-assembled aluminum oxyhydroxide nanorices with superior suspension stability for vaccine adjuvant10.1016/j.jcis.2022.07.022 ↗
87. Mallakpour, S., Nikkhoo, E., and Hussain, C.M. (2022). Application of MOF materials as drug delivery systems for cancer therapy and dermal treatment. Coord. Chem. Rev., 451.10.1016/j.ccr.2021.214262 ↗
88. Ma, D., Wang, G., Lu, J., Zeng, X., Cheng, Y., Zhang, Z., Lin, N., and Chen, Q. (2023). Multifunctional nano MOF drug delivery platform in combination therapy. Eur. J. Med. Chem., 261.10.1016/j.ejmech.2023.115884 ↗
89. An aluminum adjuvant-integrated nano-MOF as antigen delivery system to induce strong humoral and cellular immune responses10.1016/j.jconrel.2019.02.035 ↗
90. Adjuvanted quaternized chitosan composite aluminum nanoparticles-based vaccine formulation promotes immune responses in chickens10.1016/j.vaccine.2023.03.067 ↗
91. Recombinant gp350 Vaccine for Infectious Mononucleosis: A Phase 2, Randomized, Double- Blind, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of an Epstein- Barr Virus Vaccine in Healthy Young Adults10.1086/523813 ↗
92. Development of an AS04-Adjuvanted HPV Vaccine with the Adjuvant System Approach10.2165/11591760-000000000-00000 ↗
93. Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives10.1002/anie.200902672 ↗
94. He, C., He, P., Tang, X., Bai, S., Qin, M., Zhang, Y., Guo, Z., Du, G., and Sun, X. (2025). Zoledronate-loaded aluminum salt nanovaccines amplify cellular immune response by enhancing cross-presentation. Nano Res., 18.10.26599/NR.2025.94907010 ↗
95. The Importance of Surface Charge in the Optimization of Antigen–Adjuvant Interactions10.1023/A:1015843210358 ↗
96. Yu, G., Liang, Z., Yu, Z., Li, M., Yang, W., Zhang, Y., Zhao, Y., Yang, C., Xue, C., and Shi, L. (2022). Engineering the hydroxyl content on aluminum oxyhydroxide nanorod for elucidating the antigen adsorption behavior. NPJ Vaccines, 7.10.1038/s41541-022-00495-9 ↗
97. Autophagy-activating aluminum hydroxide nanovaccine for enhanced antigen presentation and antitumor immunity10.1016/j.jconrel.2024.11.018 ↗
98. Nutritional immunity: Transition metals at the pathogen–host interface10.1038/nrmicro2836 ↗
99. Chapter Seven—Metalloimmunology: The metal ion-controlled immunity10.1016/bs.ai.2019.11.007 ↗
100. Li, Y., Wang, C., Lv, H., Li, J., Zhang, X., Zhang, S., Shen, Q., Wu, Q., Liu, Y., and Peng, R. (2024). Manganese-Modified Aluminum Adjuvant Enhances both Humoral and Cellular Immune Responses. Adv. Healthc. Mater., 13.10.1002/adhm.202401675 ↗